Published On: 6/11/2024
EASL 2024 Research: Presentation by Arun J. Sanyal, MBBS, MD
Co-chair of the TARGET-NASH steering committee, Arun J. Sanyal, MBBS, MD, helped author a new Target RWE study which was presented at EASL 2024 titled “A Prospective Assessment of Disease Progression Impact on Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease.”
Focusing on metabolic dysfunction-associated stereotactic liver disease (MASLD), the study investigated disease progression impact on patient-reported outcomes (PROs) and highlights the increased burden on patients as the disease advances. Watch this video presentation by Dr. Sanyal highlighting the important study:
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
McKinley Peter
Digital Marketing Specialist
+1 (352) 514-8045
More News
-
12/09/2025
Target RWE Announces Appointment of Alan Brookhart as President of NoviSci at Target RWE -
11/25/2025
Real-World Evidence [RWE] Demonstrates Repatha’s Long-Term Cardiovascular Benefits -
11/04/2025
Target RWE Appoints Sriram Krishnan as New Chief Product Officer -
08/21/2025
Target RWE Presenting at ISPE 2025: Powering Evidence Generation with Causal Inference -
06/24/2025
Target RWE Advances Next-Generation Causal Inference Approaches in Real-World Evidence with New Publications